Allograft vasculopathyShort-term angiopeptin (cas 113294-82-9) therapy and the incidence of graft vessel disease after heart transplantation

Add time:08/17/2019    Source:sciencedirect.com

BackgroundGraft vessel disease, the major limitation for long-term success after heart transplantation, is triggered by injury to the graft vessel endothelium, resulting in the expression of adhesion molecules, the migration of leukocytes into the graft, and the release of growth factors. angiopeptin (cas 113294-82-9), a stable analog of somatostatin, is a growth-hormone inhibitor with additional anti-proliferative effects. We evaluated angiopeptin for prevention of graft vasculopathy after cardiac transplantation in the first prospective, randomized, double-blind, clinical trial.

We also recommend Trading Suppliers and Manufacturers of angiopeptin (cas 113294-82-9). Pls Click Website Link as below: cas 113294-82-9 suppliers

Prev:angiopeptin (cas 113294-82-9), the octapeptide analogue of somatostatin, decreases rat heart endothelial cell adhesiveness for mononuclear cells
Next:angiopeptin (cas 113294-82-9), a Somatostatin Analogue, Inhibits Rat Coronary Artery and Aorta Smooth Muscle Cell Proliferation Induced by the Thromboxane A2 Mimetic U46619)